Microbot Medical Net Income From Continuing Ops Over Time
| MBOT Stock | USD 1.80 0.02 1.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Microbot Medical Performance and Microbot Medical Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will Microbot introduce new products? Factors like these will boost the valuation of Microbot Medical. Expected growth trajectory for Microbot significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Microbot Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Microbot Medical using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Microbot Medical's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Microbot Medical's market price to deviate significantly from intrinsic value.
Understanding that Microbot Medical's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Microbot Medical represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Microbot Medical's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Microbot Medical and related stocks such as Vivani Medical, InspireMD, and Oramed Pharmaceuticals Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VANI | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (12.8 M) | (13.9 M) | (26.9 M) | (23.5 M) | (21.1 M) | (22.2 M) |
| NSPR | (29.2 M) | (29.2 M) | (29.2 M) | (29.2 M) | (25.1 M) | (15.6 M) | (8.5 M) | (8.4 M) | (7.2 M) | (10 M) | (10.5 M) | (14.9 M) | (18.5 M) | (19.9 M) | (32 M) | (28.8 M) | (27.4 M) |
| ORMP | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (23 M) | (37.8 M) | 5.1 M | (19.1 M) | (22 M) | (23.1 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (6.4 M) | (6.4 M) | 6.6 M | (10.5 M) | (14.8 M) | (20.8 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| CRDL | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (15.9 M) | (13.7 M) | (20.6 M) | (31.6 M) | (30.9 M) | (28 M) | (36.7 M) | (33 M) | (34.7 M) |
| ZTEK | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (2.4 M) | (1.5 M) | (3.9 M) | (12 M) | (14.4 M) | (11.7 M) | (10 M) | (9 M) | (9.5 M) |
| OVID | (446.9 K) | (446.9 K) | (446.9 K) | (446.9 K) | (446.9 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (60.5 M) | (81 M) | 122.8 M | (54.2 M) | (48.5 M) | (26.4 M) | (23.8 M) | (25 M) |
| RCEL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (10.3 M) | (8.8 M) | (12.1 M) | (24.6 M) | (24.6 M) | (42 M) | (26.6 M) | (26.7 M) | (35.4 M) | (61.8 M) | (55.7 M) | (52.9 M) |
| CLNN | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (40.4 M) | (39.4 M) | (35.5 M) | (37.2 M) |
| DCGO | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (14.8 M) | 19.2 M | 30.7 M | 10 M | 13.4 M | 15.4 M | 16.1 M |
Microbot Medical and related stocks such as Vivani Medical, InspireMD, and Oramed Pharmaceuticals Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Microbot Medical | MBOT |
| Classification | Drugs |
| Business Address | 175 Derby Street, |
| Exchange | NASDAQ Exchange |
USD 1.8
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.